Literature DB >> 14626451

Binding interactions of antagonists with 5-hydroxytryptamine3A receptor models.

Gábor Maksay1, Zsolt Bikádi, Miklós Simonyi.   

Abstract

Homology modeling was performed on the N-terminal extracellular regions of human, mouse, and guinea pig 5-hydroxytryptamine type 3A receptors (5-HT3R) based on the 24% sequence homology with and on the crystal structure of the snail acetylcholine binding protein (AChBP). Docking of 5-HT3 antagonists granisetron, tropisetron, ondansetron, dolasetron ('setrons), and (+)-tubocurarine suggests an aromatic binding cleft behind a hydrophilic vestibule. Several intra- and interface interactions, H-bonds, and salt bridges stabilize the pentameric structure and the binding cleft. The planar rings of antagonists are intercalated between aromatic side-chains (W183-Y234, Y143-Y153). S227 donates H-bonds to the carbonyl groups of 'setrons. The tertiary ammonium ions interact with E236, N128 or E129, and/or W90 (cation-pi interaction). This offers a molecular explanation of the pharmacophore models of 5-HT3R antagonists. Docking artifacts suggest some ambiguities in the binding loops A and C of the 5-HT3AR models. Lower potencies of (+)-tubocurarine for human, and those of tropisetron for guinea pig 5-HT3ARs can be attributed to steric differences of I/S230 in the binding cleft and to distinct binding interactions with E229 and S227, respectively. Ligand binding interferes with crucial intra- and interface interactions along the binding cleft.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14626451     DOI: 10.1081/rrs-120025568

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  14 in total

1.  Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor.

Authors:  M Lochner; S C R Lummis
Journal:  Biophys J       Date:  2010-04-21       Impact factor: 4.033

2.  Unbinding pathways of an agonist and an antagonist from the 5-HT3 receptor.

Authors:  A J Thompson; P-L Chau; S L Chan; S C R Lummis
Journal:  Biophys J       Date:  2005-12-30       Impact factor: 4.033

3.  Structure-based 3D-QSAR studies on thiazoles as 5-HT3 receptor antagonists.

Authors:  Li-Ping Zhu; De-Yong Ye; Yun Tang
Journal:  J Mol Model       Date:  2006-09-05       Impact factor: 1.810

4.  Defining the roles of Asn-128, Glu-129 and Phe-130 in loop A of the 5-HT3 receptor.

Authors:  Nora L Sullivan; Andrew J Thompson; Kerry L Price; Sarah C R Lummis
Journal:  Mol Membr Biol       Date:  2006 Sep-Oct       Impact factor: 2.857

Review 5.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

6.  Ondansetron and granisetron binding orientation in the 5-HT(3) receptor determined by unnatural amino acid mutagenesis.

Authors:  Noah H Duffy; Henry A Lester; Dennis A Dougherty
Journal:  ACS Chem Biol       Date:  2012-08-15       Impact factor: 5.100

7.  Molecular modeling of the GABA(C) receptor ligand-binding domain.

Authors:  Neil J Harrison; Sarah C R Lummis
Journal:  J Mol Model       Date:  2005-10-26       Impact factor: 1.810

8.  Tyrosine residues that control binding and gating in the 5-hydroxytryptamine3 receptor revealed by unnatural amino acid mutagenesis.

Authors:  Darren L Beene; Kerry L Price; Henry A Lester; Dennis A Dougherty; Sarah C R Lummis
Journal:  J Neurosci       Date:  2004-10-13       Impact factor: 6.167

Review 9.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 10.  The 5-HT3 receptor--the relationship between structure and function.

Authors:  Nicholas M Barnes; Tim G Hales; Sarah C R Lummis; John A Peters
Journal:  Neuropharmacology       Date:  2008-08-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.